149 related articles for article (PubMed ID: 3207229)
1. [Oral dantrolene in a parturient with myotonic dystrophy and susceptibility to malignant hyperthermia].
Houvenaeghel M; Achilli-Cornesse E; Jullian-Papouin H; Martin-Meyssonier A; Manelli JC
Ann Fr Anesth Reanim; 1988; 7(5):408-11. PubMed ID: 3207229
[TBL] [Abstract][Full Text] [Related]
2. [Caesarean section in a patient with past history of fulminant malignant hyperthermia].
Goto S; Ogata K; Fujie T; Fujigaki T; Nakamura H; Yukinari T; Shibata O
Masui; 1993 Feb; 42(2):271-5. PubMed ID: 8437362
[TBL] [Abstract][Full Text] [Related]
3. [Combined spinal-epidural anesthesia for cesarean section in a parturient with myotonic dystrophy].
Mori K; Mizuno J; Nagaoka T; Harashima T; Morita S
Masui; 2010 Aug; 59(8):1000-3. PubMed ID: 20715526
[TBL] [Abstract][Full Text] [Related]
4. [Transient normalisation of CK blood levels in patients susceptible to malignant hyperthermia by oral administration of dantrolene (author's transl)].
Bernhardt D
Anaesthesist; 1982 May; 31(5):252-4. PubMed ID: 7103034
[TBL] [Abstract][Full Text] [Related]
5. The anaesthetic management of the malignant hyperthermia susceptible parturient.
Douglas MJ; McMorland GH
Can Anaesth Soc J; 1986 May; 33(3 Pt 1):371-8. PubMed ID: 3719439
[TBL] [Abstract][Full Text] [Related]
6. Creatine phosphokinase (CPK) levels in pregnancy: a case report and a discussion of the value of CPK levels in the prediction of possible malignant hyperpyrexia.
Isherwood DM; Ridley J; Wilson J
Br J Obstet Gynaecol; 1975 Apr; 82(4):346-9. PubMed ID: 1125158
[TBL] [Abstract][Full Text] [Related]
7. Anaesthesia for caesarean delivery of a malignant hyperthermia susceptible parturient.
Lucy SJ
Can J Anaesth; 1994 Dec; 41(12):1220-6. PubMed ID: 7867120
[TBL] [Abstract][Full Text] [Related]
8. Malignant hyperthermia: a possible new variant.
Lee DS; Adams JP; Zimmerman JE
Can Anaesth Soc J; 1985 May; 32(3 Pt 1):268-71. PubMed ID: 4005678
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and management of susceptibility to malignant hyperthermia in pregnancy.
Sorosky JI; Ingardia CJ; Botti JJ
Am J Perinatol; 1989 Jan; 6(1):46-8. PubMed ID: 2910318
[TBL] [Abstract][Full Text] [Related]
10. Successful use of dantrolene sodium in human malignant hyperthermia syndrome: a case report.
Friesen CM; Brodsky JB; Dillingham MF
Can Anaesth Soc J; 1979 Jul; 26(4):319-21. PubMed ID: 509349
[TBL] [Abstract][Full Text] [Related]
11. Malignant hyperthermia susceptibility: anaesthetic implications and risk stratification.
Ben Abraham R; Cahana A; Krivosic-Horber RM; Perel A
QJM; 1997 Jan; 90(1):13-8. PubMed ID: 9093584
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of dantrolene following oral administration in malignant hyperthermia-susceptible patients.
Allen GC; Cattran CB; Peterson RG; Lalande M
Anesthesiology; 1988 Dec; 69(6):900-4. PubMed ID: 3057938
[TBL] [Abstract][Full Text] [Related]
13. Malignant hyperthermia following preoperative oral administration of dantrolene.
Fitzgibbons DC
Anesthesiology; 1981 Jan; 54(1):73-5. PubMed ID: 7457985
[No Abstract] [Full Text] [Related]
14. Anesthetic management of a parturient with myotonia atrophica.
Hook R; Anderson EF; Noto P
Anesthesiology; 1975 Dec; 43(6):689-92. PubMed ID: 1081353
[No Abstract] [Full Text] [Related]
15. [Prophylaxis with dantrolene sodium in 2 patients with susceptibility to malignant hyperthermia].
Navas E; Sánchez-Peña J; Gutiérrez-Crespo A
Rev Esp Anestesiol Reanim; 1992; 39(5):309-11. PubMed ID: 1410753
[TBL] [Abstract][Full Text] [Related]
16. Dantrolene in pregnancy: lack of adverse effects on the fetus and newborn infant.
Shime J; Gare D; Andrews J; Britt B
Am J Obstet Gynecol; 1988 Oct; 159(4):831-4. PubMed ID: 3177531
[TBL] [Abstract][Full Text] [Related]
17. Anesthetic management of a parturient with myotonia dystrophica: a case report.
Camann WR; Johnson MD
Reg Anesth; 1990; 15(1):41-3. PubMed ID: 2275912
[TBL] [Abstract][Full Text] [Related]
18. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.
Ward A; Chaffman MO; Sorkin EM
Drugs; 1986 Aug; 32(2):130-68. PubMed ID: 3527659
[TBL] [Abstract][Full Text] [Related]
19. Malignant hyperthermia: current perspectives.
Felice-Johnson J; Sudds T; Bennett G
Am J Hosp Pharm; 1981 May; 38(5):646-51. PubMed ID: 7282692
[TBL] [Abstract][Full Text] [Related]
20. Clinical effects of intravenously administered dantrolene.
Wedel DJ; Quinlan JG; Iaizzo PA
Mayo Clin Proc; 1995 Mar; 70(3):241-6. PubMed ID: 7861811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
